Poor patient compliance with drug dosing regimens can be a major impediment to effective treatments. Here we discuss how to leverage patient adherence with Eye care medications and how to choose a packaging format that will meet regulatory authorities’ requirements.
Presented by Matthias Birkhoff, V.P. Business Development, Aptar Pharma and Dr. Degenhard Marx, Director Scientific Affairs, Aptar Pharma this webinar reviews new technologies in ophthalmic drug delivery to optimize patient adherence and compliance in eye care
Poor patient compliance with drug dosing regimens can be a major impediment to effective treatments. Eye care diseases such as AMD and Glaucoma are potentially blinding chronic diseases, requiring life-long medical therapy. Failure to adhere to proper treatment may lead to disease progression and visual loss, not to mention economic consequences. Even though the topical application of ophthalmic drugs is quite straightforward, it is common knowledge that poor compliance is widespread. It is often due to a mix of several factors, including drops that sting and the difficulty of applying drops accurately, particularly for older patients. Preservatives play a prominent role in this unfavorable mix, often to the patient’s detriment, so offering preservative-free formulations is of major interest.
Considering that in terms of both efficacy and safety, topical delivery of drugs, especially for front-of-the-eye indications, is superior to all other administration routes, this presentation shows the available options and discusses future trends, in particular regarding preservatives and debatable additives, but also novel approaches like “Connected Eye Care”.
Specific strategies to address the issues of patient compliance and drug delivery optimization are discussed. In addition, limitations and regulatory hurdles associated with future methods are also reviewed. Finally, the presentation examines approaches available now and in the near future that enhance efficacy by improving delivery of ophthalmic formulations.
Vice President Business Development, Aptar Pharma
Matthias Birkhoff is Vice President Business Development at Aptar Pharma. In this role he is responsible for Aptar Pharma’s Eye Care program and coordinates research and development
activities, microbiological assessment and commercial strategies. Matthias started his career in pharmaceutical sales at a major multinational pharmaco before joining Aptar Pharma nineteen years ago. Prior to his involvement in Business Development and Marketing, Matthias oversaw sales in the AsiaPacific region. He studied medicine at the University of Dusseldorf, Germany and holds a nursing degree.
Matthias has recently spoken at international events, such as Nasal Drug Delivery, Pharmaceutical Plastics, Interphex, CPhI, Pharmapack, AAPS, and the IPA conference in Mumbai/India.
Dr. Degenhard Marx
Director Scientific Affairs, Aptar Pharma
Dr. Degenhard Marx is a Director of Scientific Affairs within the Aptar Pharma Consumer Health Care Division. Following his study of Veterinary Medicine, and the successful completion of his thesis at the University of Leipzig in 1992, he joined the pharmaceutical industry. In 2001 he took over a senior research position at Altana Pharma/Nycomed in Constance, Germany. During his time in the pharmaceutical industry he has gained extensive experience in the drug development of anti-inflammatory and cardiovascular drugs. In 2008, he became Business Development Manager within Aptar Pharma. He is now Director Scientific Affairs within the Aptar Pharma Consumer Health Care division.